Maccura Biotechnology Co.Ltd(300463)
Announcement on resolutions of the first meeting of the 5th board of directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions. 1、 Convening of board meeting
1. The notice of the first meeting of the Fifth Board of directors of Maccura Biotechnology Co.Ltd(300463) (hereinafter referred to as “the company”) was sent and delivered to all directors by mail, SMS and telephone on January 7, 2022.
2. The meeting was held in the company’s conference room on January 17, 2022 by combining on-site and communication.
3. 9 directors should attend the meeting and 9 actually attended the meeting.
4. The meeting was convened and presided over by Mr. Tang Yong, chairman of the board of directors. The supervisors and some senior managers of the company attended the meeting as nonvoting delegates.
5. The convening, convening and voting procedures of this meeting comply with the company law of the people’s Republic of China (hereinafter referred to as the “company law”) and other laws, regulations and normative documents, as well as the relevant provisions of the Maccura Biotechnology Co.Ltd(300463) articles of Association (hereinafter referred to as the “articles of association”), and the meeting is legal and effective. 2、 Deliberations of the board meeting
After careful deliberation by the directors attending the meeting, the following proposals were adopted by on-site written voting: (I) the proposal on electing the chairman of the Fifth Board of directors of the company was deliberated and adopted
In accordance with the relevant provisions of the company law and the articles of association, the board of directors agreed to elect Mr. Tang Yong as the chairman of the Fifth Board of directors of the company, and the term of office is from the date of deliberation and approval of the current board of directors to the expiration of the fifth board of directors. See the attachment for the resume of Mr. Tang Yong.
Voting results: 9 in favor, 0 against and 0 abstention (II) the proposal on election of members of the special committee of the Fifth Board of directors of the company was deliberated and adopted
In accordance with the company law, the guidelines for the governance of listed companies, the Listing Rules of Shenzhen Stock Exchange on the gem, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for the standardized operation of companies listed on the gem and other relevant laws and regulations and the relevant provisions of the company’s charter, the Fifth Board of directors of the company established a strategy committee The remuneration and assessment committee, nomination committee, audit committee and the board of directors agree to elect the following persons as members of the special committee of the Fifth Board of directors. The specific list is as follows:
(1) Mr. Tang Yong, Mr. Wang Dengming, Mr. Wu Mingjian, Mr. Xu Shengguo and Mr. Liao Zhenzhong were elected as members of the strategy committee of the Fifth Board of directors of the company, of which Mr. Tang Yong was the chairman.
(2) Elect Mr. Liao Zhenzhong, Mr. Fu daiguo, Mr. Liang Kaicheng, Mr. Tang Yong and Mr. Liu Qilin as members of the remuneration and assessment committee of the Fifth Board of directors of the company, of which Mr. Liao Zhenzhong is the chairman.
(3) Elect Mr. Liang Kaicheng, Mr. Fu daiguo, Mr. Liao Zhenzhong, Mr. Tang Yong and Mr. Wang Dengming as members of the nomination committee of the Fifth Board of directors of the company, of which Mr. Liang Kaicheng is the chairman.
(4) Elect Mr. Fu daiguo, Mr. Liao Zhenzhong, Mr. Liang Kaicheng, Mr. Wang Dengming and Mr. Liu Qilin as members of the audit committee of the Fifth Board of directors of the company, of which Mr. Fu daiguo is the chairman.
The term of office of the above members shall be from the date of deliberation and approval of the current board of directors to the expiration of the Fifth Board of directors.
Voting results: 9 in favor, 0 against and 0 abstention (III) the proposal on the appointment of senior managers and securities affairs representatives of the company was deliberated and adopted
Upon the nomination of the chairman of the company and the nomination and review of the nomination committee of the board of directors, the company plans to reappoint Mr. Wu Mingjian as the general manager of the company; Mr. Xu Shengguo was reappointed as the director of market operation, Mr. long TengXiang as the director of R & D (Reagent), Mr. Wang Weijia as the director of R & D (instrument), Ms. Yang Hui as the director of production (Reagent), Mr. Wang Zhen as the director of production (instrument), Mr. Li Bo as the director of business, Ms. Yin Shan as the chief financial officer and Ms. Yu Ping as the chief administrative officer; Renew the appointment of Ms. Shi Wei as director of strategic investment and Secretary of the board of directors; Renew the appointment of Ms. Zhang Wenjun as securities representative. The term of office of the above-mentioned personnel shall be from the date of deliberation and approval of the current board of directors to the expiration of the Fifth Board of directors (see Annex for resume).
Independent directors have expressed their independent opinions on the proposal.
Voting results: 9 in favor, 0 against and 0 abstention. III. documents for future reference
1. Resolution of the first meeting of the 5th board of directors
2. Independent opinions of independent directors on matters related to the first meeting of the Fifth Board of directors
It is hereby announced.
Attachment: resume of chairman, resume of senior management and securities affairs representative
Maccura Biotechnology Co.Ltd(300463) board of directors January 18, 2002 Annex: (I) resume of the chairman
Mr. Tang Yong, born in July 1963, Chinese nationality, without permanent residency abroad, has a college degree. He has been devoted to the product, market and technology development of in vitro diagnosis industry, and once worked in Sichuan Institute of traditional Chinese medicine; After the establishment of Mike Technology (the predecessor of ” Maccura Biotechnology Co.Ltd(300463) ” in 1994), he once served as the chairman and general manager of Mike technology. Now he is the chairman of the company and vice chairman of the medical laboratory industry branch of the National Health Industry Enterprise Management Association.
As of the date of this announcement, Mr. Tang Yong holds 68062301 shares of the company and is one of the main shareholders and actual controllers of the company. In addition, he has no relationship with other shareholders holding more than 5% shares of the company, as well as other directors, supervisors and senior managers of the company. There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person. (II) resumes of senior managers and securities affairs representatives
Mr. Wu Mingjian, born in December 1975, Chinese nationality, without permanent residency abroad, master’s degree, senior accountant. He once worked in Sichuan Guoli Network Technology Co., Ltd. and Chengdu classic Information Technology Co., Ltd. of Guangdong Guoli group. He has worked in Mike technology company since 2002. He once served as the company’s financial manager, commercial director and strategic investment director. He is now the company’s director and general manager. As of the date of this announcement, Mr. Wu Mingjian holds 1104642 shares of the company. In addition, he is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Mr. Xu Shengguo, born in November 1978, Chinese nationality, without permanent residency abroad, has a master’s degree. He has worked in Mike technology since 2001 and is now the director and director of market operation of the company.
As of the date of this announcement, Mr. Xu Shengguo holds 162919 shares of the company. In addition, he is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Mr. long TengXiang, born in August 1981, Chinese nationality, without permanent residency abroad, has a master’s degree. Graduated from biochemistry and molecular biology, School of laboratory medicine, Chongqing Medical University, worked in the company since 2005, once served as the chief engineer of the company’s reagent production system, and now serves as the company’s R & D Director (Reagent). Mr. long TengXiang is now a member of the National Technical Committee for standardization of medical clinical laboratory and in vitro diagnostic system (SAC / tc136), the National Technical Committee for standardization of biochemical testing (SAC / tc387), the professional committee of labeling immunoassay of China Association for analysis and testing, the standardization group of laboratory medicine sub group of China Medical Equipment Association Member of luminous standardization and application group of laboratory medicine branch of China Medical Equipment Association, member of Teaching Steering Committee of medical technology specialty of Sichuan ordinary undergraduate colleges and universities (2021-2025), and risk assessment expert of Sichuan entry-exit special goods.
Up to now, Mr. long TengXiang holds 75459 shares of the company. In addition, he is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Mr. Wang Weijia, born in November 1983, Chinese nationality, without permanent residency abroad, has a master’s degree. Graduated from biomedical engineering of Southwest Jiaotong University, worked in the company since 2010, once served as the manager of Maccura Biotechnology Co.Ltd(300463) R & D department, and now serves as the director (instrument) of Maccura Biotechnology Co.Ltd(300463) .
Up to now, Mr. Wang Weijia holds 67913 shares of the company. In addition, he is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Ms. Yang Hui, born in March 1967, Chinese nationality, without permanent residency abroad, with a bachelor’s degree. He graduated from Chongqing Medical University in 1990, majored in medical laboratory, and once worked in the laboratory department of China Metallurgical hospital. He has worked in the company since 2001. He once served as the workshop director of the production department, the manager of the production management department, the chief engineer of the reagent production system and the shareholder supervisor of the company. He is now the general production supervisor (Reagent) of the company.
Up to now, Ms. Yang Hui holds 2745500 shares of the company. In addition, she is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Mr. Wang Zhen, born in April 1970, Chinese nationality, without permanent residency abroad, has a master’s degree. He once worked in Sichuan Jianyang food company, Shenzhen Far East Hotel and Wenyuan restaurant of Zhonghua Book Company on Wangfujing Group Co.Ltd(600859) street in Beijing. He has worked in the company since 2000 and is now the production director (instrument) of the company.
Up to now, Mr. Wang Zhen holds 48875 shares of the company. In addition, he is not related to other shareholders holding more than 5% of the shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Mr. Li Bo, born in January 1977, Chinese nationality, without permanent residency abroad, has a master’s degree. He graduated from the medical laboratory specialty of Chengdu Medical College in 2001 and obtained the master of Business Administration (EMBA) degree of senior managers of Southwest University of Finance and economics in 2016. He has worked in the company since 2001 and is now the business director of the company.
As of the date of this announcement, Mr. Li Bo does not hold shares of the company and has no relationship with the controlling shareholder, actual controller, other shareholders holding more than 5% shares of the company, and other directors, supervisors and senior managers of the company; There are no circumstances specified in Article 146 of the company law, and there are no circumstances specified in article 3.2.4 of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – Guidelines for standardized operation of companies listed on GEM; There is no punishment by the CSRC and other relevant departments or the stock exchange; Not a dishonest person.
Ms. Yin Shan, born in June 1980, Chinese nationality, without permanent residency abroad, has a master’s degree. Graduated from Sichuan Institute of technology in 2002, majored in financial management, and obtained the national master of Business Administration (MBA) from Southwest Jiaotong University in 2018. He has worked in the company since 2004, once served as the financial director and financial manager of Maccura Biotechnology Co.Ltd(300463) financial management department, and now serves as the financial director of Maccura Biotechnology Co.Ltd(300463) . Up to now, Ms. Yin Shan holds 39930 shares of the company. In addition, she has no relationship with other shareholders holding more than 5% of the company’s shares, as well as other directors, supervisors and senior managers of the company; There is no first instance of the company law
